---

Nanoparticulate based ocular drug delivery technology: “Nanoemulsion a novel approach”

---

Original Article

Author Details : Kiranbala Jain*, Meenakshi Bharkatiya

Volume : 7, Issue : 3, Year : 2020

Article Page : 168-176

https://doi.org/10.18231/j.ijpp.2020.029

Suggest article by email

Get Permission

---

Abstract

Many ocular diseases or disorders require frequent administration of the drug. But poor ocular
bioavailability of drugs (< 1> epithelial layers protect the eye and consequently limit the penetration of ocular drugs. In order to
overcome the shortcomings of the standard form of ophthalmic dosage, much has been done to improve
the absorption of pre-corneal drugs and to reduce the loss of pre-corneal drugs. Ophthalmic formulation
based on Nanotechnology is one of the approaches to internal and external drug delivery. Nanotechnology
systems with the right particle size can be made to ensure minimal irritation, adequate bioavailability,
and tissue compatibility. Many of them have shown promising results in improving ocular availability.
Nanoemulsions are the colloidal oil in water (o/w) or water in oil (w/o) nano-dispersions and homogenous
systems, stabilized by surfactants and co-surfactants to reduce the interfacial tension. Typically, the droplet
size is <150> homogeneous and thermodynamically stable systems. They offer a high penetration rate into the deeper
layers of tissue due to the nano-droplet size range.

Keywords: Ocular nanotechnology, Novel ophthalmic drug delivery, Nanoemulsions, Microemulsions,
Nanodispersions, Nanosize drug.

How to cite : Jain K , Bharkatiya M , Nanoparticulate based ocular drug delivery technology: “Nanoemulsion a novel approach”. Indian J Pharm Pharmacol 2020;7(3):168-176

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.